Is CLL the Second Cancer? A Single Center Retrospective Analysis of Secondary Malignancies (SM) in Patients with Chronic Lymphocytic Leukemia (CLL)

被引：0
|
作者：
Akhtar, Othman Salim [1 ]
Singh, Anil [2 ]
Groman, Adrienne [2 ]
Hernandez-Ilizaliturri, Francisco J. [2 ]
机构：
[1] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Dept Med, Buffalo, NY USA
[2] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2018年 / 18卷
关键词：
CLL; secondary cancers; prostate cancer; bladder cancer; renal cell carcinoma;
D O I：
10.1016/j.clml.2018.07.087
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CLL-303
引用
收藏
页码：S219 / S219
页数：1
相关论文
共 50 条
  • [1] Ibrutinib for Chronic Lymphocytic Leukemia (CLL): A Single Center Experience in Bogota, Colombia
    Bohorquez, Leonardo
    Abello, Virginia
    Helena Solano, Maria
    Casas, Claudia
    Espinosa, Daniel
    Leon, Guillermo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S285 - S285
  • [2] First Line Treatment of Chronic Lymphocytic Leukemia (CLL) Patients With Obinutuzumab Based Therapy: Single-Center Experience
    Trajkova, Sanja
    Pivkova-Veljanovska, Aleksandra
    Krstevska-Balkanov, Svetlana
    Popova-Labacevska, Marija
    Ridova, Nevenka
    Stojanovska-Jakimovska, Simona
    Cvetanovski, Milche
    Chadievski, Lazar
    Kocoski, Bozidar
    Panovska-Stavridis, Irina
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S326 - S326
  • [3] Second Primary Malignancies (SPMs) in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With the Combination of a Targeted Agent With an Antibody in 4 Phase 2 Trials of the German CLL Study Group (GCLLSG)
    Goergen, Ellinor
    von Tresckow, Julia
    Giza, Adam
    Robrecht, Sandra
    Fink, Anna-Maria
    Fischer, Kirsten
    Al-Sawaf, Othman
    Fuerstenau, Moritz
    Simon, Florian
    Kutsch, Nadine
    Nieper, Pascal
    Tausch, Eugen
    Ritgen, Matthias
    Boettcher, Sebastian
    Kreuzer, Karl-Anton
    Stilgenbauer, Stephan
    Langerbeins, Petra
    Eichhorst, Barbara
    Hallek, Michael
    Cramer, Paula
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S354 - S355
  • [4] Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL)
    Thompson, Philip A.
    Burger, Jan A.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (01) : 31 - 42
  • [5] Utilization of Chronic Lymphocytic Leukemia - International Prognostic Index (CLL-IPI) for pPrognostic sStratification in nNewly dDiagnosed CLL patients
    Alhadi, Noor-Ul-Huda
    Malik, Hamid Saeed
    Buzdar, Manzar
    Mahmood, Rafia
    Khursheed, Ayesha
    Khan, Aysha
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S344 - S344
  • [6] Clinical utility of CLL-IPI scoring system in Pakistani Chronic Lymphocytic Patients: A single center experience
    Hameed, Aisha
    Sajid, Nadia
    Fayyaz, Muhammad
    Khaliq, Shagufta
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2024, 40 (04) : 701 - 705
  • [7] JS']JSH practical guidelines for hematological malignancies, 2023: leukemia-5. Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
    Takamatsu, Yasushi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2025, : 432 - 449
  • [8] Pathogenesis, prevalence, and prognostic significance of cytopenias in chronic lymphocytic leukemia (CLL): a retrospective comparative study of 213 patients from a national CLL database of 1,518 cases
    Lev Shvidel
    Tamar Tadmor
    Andrei Braester
    Osnat Bairey
    Naomi Rahimi-Levene
    Yair Herishanu
    Abraham Klepfish
    Mordechai Shtalrid
    Alain Berrebi
    Aaron Polliack
    Annals of Hematology, 2013, 92 : 661 - 667
  • [9] Pathogenesis, prevalence, and prognostic significance of cytopenias in chronic lymphocytic leukemia (CLL): a retrospective comparative study of 213 patients from a national CLL database of 1,518 cases
    Shvidel, Lev
    Tadmor, Tamar
    Braester, Andrei
    Bairey, Osnat
    Rahimi-Levene, Naomi
    Herishanu, Yair
    Klepfish, Abraham
    Shtalrid, Mordechai
    Berrebi, Alain
    Polliack, Aaron
    ANNALS OF HEMATOLOGY, 2013, 92 (05) : 661 - 667
  • [10] Long Term Outcomes and Secondary Malignancies in 673 Patients Treated With Oral Fludarabine and Intravenous Rituximab (FR) for Chronic Lymphocytic Leukemia (CLL) in British Columbia (BC), CanadaElys
    VanderVeer, Elysha
    Huang, Steven J. T.
    Bruyere, Helene
    Li, Charles
    Ramadan, Khaled
    Villa, Diego
    Scott, David W.
    Savage, Kerry J.
    Connors, Joseph M.
    Sehn, Laurie H.
    Toze, Cynthia L.
    Gerrie, Alina S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S331 - S331
12345